Advertisement
Screener

MeiraGTx Holdings plc (MGTX) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

MeiraGTx Holdings plc Increase (Decrease) in Deferred Revenue

MeiraGTx Holdings plc (MGTX) reported Increase (Decrease) in Deferred Revenue of -$50.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-05-14

  • MeiraGTx Holdings plc increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$50.00K.
  • MeiraGTx Holdings plc increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$36.00K, a 101.29% decline year-over-year.
  • MeiraGTx Holdings plc increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $1.02M, a 69.22% decline year-over-year.
  • MeiraGTx Holdings plc increase (decrease) in deferred revenue for the quarter ending 2025-06-30 was -$1.39M, a 2343.55% decline year-over-year.
  • MeiraGTx Holdings plc increase (decrease) in deferred revenue for fiscal 2025 was -$731.00K, a 102.74% decline from fiscal 2024.
  • MeiraGTx Holdings plc increase (decrease) in deferred revenue for fiscal 2024 was $26.66M.
  • MeiraGTx Holdings plc increase (decrease) in deferred revenue for fiscal 2023 was -$7.51M.
  • MeiraGTx Holdings plc increase (decrease) in deferred revenue for fiscal 2022 was -$15.92M.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 3 month as first filedIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 6 month as first filedIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 9 month as first filedIncrease (Decrease) in Deferred Revenue 12 monthIncrease (Decrease) in Deferred Revenue 12 month as first filed
2026-03-31-$50.00K
10-Q · filed 2026-05-14
-$86.00K
derived: sum of 2 quarters · filed 2026-05-14
$939.00K
derived: sum of 3 quarters · filed 2026-05-14
-$452.00K
derived: sum of 4 quarters · filed 2026-05-14
2025-12-31-$36.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$989.00K
derived: sum of 2 quarters · filed 2026-03-30
-$402.00K
derived: sum of 3 quarters · filed 2026-03-30
-$731.00K
10-K · filed 2026-03-30
2025-09-30$1.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$366.00K
derived: sum of 2 quarters · filed 2025-11-13
-$695.00K
10-Q · filed 2025-11-13
$2.10M
derived: sum of 4 quarters · filed 2026-05-14
2025-06-30-$1.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
-$1.72M
10-Q · filed 2025-08-14
$1.08M
derived: sum of 3 quarters · filed 2026-05-14
$4.41M
derived: sum of 4 quarters · filed 2026-05-14
2025-03-31-$329.00K
10-Q · filed 2026-05-14
$2.47M
derived: sum of 2 quarters · filed 2026-05-14
$5.80M
derived: sum of 3 quarters · filed 2026-05-14
$5.86M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31$2.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$6.13M
derived: sum of 2 quarters · filed 2026-03-30
$6.19M
derived: sum of 3 quarters · filed 2026-03-30
$26.66M
10-K · filed 2026-03-30
2024-09-30$3.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$3.39M
derived: sum of 2 quarters · filed 2025-11-13
$23.87M
10-Q · filed 2025-11-13
$28.34M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$62.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$20.54M
10-Q · filed 2025-08-14
$25.01M
derived: sum of 3 quarters · filed 2025-08-14
$19.91M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$20.48M
10-Q · filed 2025-05-13
$24.95M
derived: sum of 2 quarters · filed 2025-05-13
$19.84M
derived: sum of 3 quarters · filed 2025-05-13
$16.30M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$4.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13
-$632.00K
derived: sum of 2 quarters · filed 2025-03-13
-$4.17M
derived: sum of 3 quarters · filed 2025-03-13
-$7.51M
10-K · filed 2025-03-13
2023-09-30-$5.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
-$8.64M
derived: sum of 2 quarters · filed 2024-11-13
-$11.98M
10-Q · filed 2024-11-13
-$6.69M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30-$3.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
-$6.87M
10-Q · filed 2024-08-12
-$1.59M
derived: sum of 3 quarters · filed 2024-08-12
-$6.40M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$3.33M
10-Q · filed 2024-05-09
$1.95M
derived: sum of 2 quarters · filed 2024-05-09
-$2.86M
derived: sum of 3 quarters · filed 2024-05-09
-$13.62M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$5.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15
$472.00K
derived: sum of 2 quarters · filed 2024-03-15
-$10.29M
derived: sum of 3 quarters · filed 2024-03-15
-$15.92M
10-K · filed 2024-03-15
2022-09-30-$4.82M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$15.57M
derived: sum of 2 quarters · filed 2023-11-14
-$21.21M
10-Q · filed 2023-11-14
-$12.04M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30-$10.76M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$16.39M
10-Q · filed 2023-08-10
-$7.22M
derived: sum of 3 quarters · filed 2023-08-10
-$14.17M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$5.63M
10-Q · filed 2023-05-11
$3.54M
derived: sum of 2 quarters · filed 2023-05-11
-$3.41M
derived: sum of 3 quarters · filed 2023-05-11
-$8.53M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$9.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14
$2.22M
derived: sum of 2 quarters · filed 2023-03-14
-$2.89M
derived: sum of 3 quarters · filed 2023-03-14
-$7.49M
10-K · filed 2023-03-14
2021-09-30-$6.95M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
-$12.06M
derived: sum of 2 quarters · filed 2022-11-10
-$16.66M
10-Q · filed 2022-11-10
-$20.45M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$5.12M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
-$9.71M
10-Q · filed 2022-08-11
-$13.50M
derived: sum of 3 quarters · filed 2022-08-11
-$18.59M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$4.59M
10-Q · filed 2022-05-12
-$8.38M
derived: sum of 2 quarters · filed 2022-05-12
-$13.47M
derived: sum of 3 quarters · filed 2022-05-12
-$15.95M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31-$3.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10
-$8.88M
derived: sum of 2 quarters · filed 2022-03-10
-$11.35M
derived: sum of 3 quarters · filed 2022-03-10
-$15.56M
10-K · filed 2022-03-10
-$15.56M
10-K · filed 2021-03-11
2020-09-30-$5.09M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$7.57M
derived: sum of 2 quarters · filed 2021-11-10
-$11.78M
10-Q · filed 2021-11-10
-$11.78M
10-Q · filed 2020-11-05
-$19.15M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30-$2.47M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11
-$6.68M
10-Q · filed 2021-08-11
-$6.68M
10-Q · filed 2020-08-06
-$14.06M
derived: sum of 3 quarters · filed 2021-08-11
-$17.21M
derived: sum of 4 quarters · filed 2021-08-11
2020-03-31-$4.21M
10-Q · filed 2021-05-11
-$4.21M
10-Q · filed 2020-05-07
-$11.59M
derived: sum of 2 quarters · filed 2021-05-11
-$14.74M
derived: sum of 3 quarters · filed 2021-05-11
-$17.16M
derived: sum of 4 quarters · filed 2021-05-11
2019-12-31-$7.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11
-$10.53M
derived: sum of 2 quarters · filed 2021-03-11
-$12.95M
derived: sum of 3 quarters · filed 2021-03-11
$85.74M
10-K · filed 2021-03-11
2019-09-30-$3.15M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$5.57M
derived: sum of 2 quarters · filed 2020-11-05
$93.12M
10-Q · filed 2020-11-05
2019-06-30-$2.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
$96.27M
10-Q · filed 2020-08-06
2019-03-31$98.69M
10-Q · filed 2020-05-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vor Biopharma Inc. (VOR)United States$1.091B1.60
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10